Shared Decision Making in Patients With Lung Cancer

Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Jan 2, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on helping patients with lung adenocarcinoma, a type of lung cancer, make informed decisions about whether to undergo molecular testing during their surgery. The researchers are developing a tool called the Decision Aid for Lung Cancer Molecular Testing (DA_LCMT) to support shared decision-making between patients and their healthcare providers. This means patients will have the opportunity to discuss their options and preferences regarding the testing, which can provide important information for their treatment.

To participate in the trial, you need to be at least 18 years old and have been diagnosed with primary invasive adenocarcinoma of the lung during surgery. You can join whether or not you have made a decision about molecular testing. The trial is currently recruiting participants, and those involved can expect to contribute to the development of resources that help other patients navigate this important choice in their cancer care. It's important to note that participants should be able to understand the research content to be eligible for the study.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• Patients of decision-making need assessment:
• • 1) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not).
• Other stakeholders of decision-making need assessment:
• • 1) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.
• Patients of Cognitive debriefing/Alpha tests:
• • 1) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not.
• other stakeholders of Cognitive debriefing/Alpha tests:
• • 1) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.
• Patients of field testing /Beta tests:
• • 1) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not.
• Clinician of field testing /Beta tests:
• • 1) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study.
• Exclusion criteria:
• • Inability to understand the research content.